Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trial.

Zoé Léonie Elise van KempenErwin L J HoogervorstMike P WattjesNynke F KalkersJop P MostertBirgit I Lissenberg-WitteAnnick de VriesAnja Ten BrinkeBob W van OostenFrederik BarkhofCharlotte E TeunissenBernard M J UitdehaagTheo RispensJoep Killestein

Published in: Neurology (2020)

This study provides Class IV evidence that personalized extended interval dosing of natalizumab does not result in recurrence of disease activity in stable patients with RRMS.

Keyphrases

disease activity
multiple sclerosis
rheumatoid arthritis
systemic lupus erythematosus
rheumatoid arthritis patients
ankylosing spondylitis
mass spectrometry
clinical trial
study protocol
ms ms
randomized controlled trial
phase iii
cross sectional
open label